Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Planned phase III trial of inhaled liposomal amikacin (ARIKAYCE) in patients with non-tuberculous mycobacteria (NTM) lung infections

Trial Profile

Planned phase III trial of inhaled liposomal amikacin (ARIKAYCE) in patients with non-tuberculous mycobacteria (NTM) lung infections

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Nontuberculous mycobacterium infections; Respiratory tract infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Insmed
  • Most Recent Events

    • 22 Sep 2014 New trial record
    • 04 Aug 2014 According to an Insmed media release, the company will proceed with this second Phase 3 study which will be designed to confirm, in as short a timeframe as possible, the positive culture conversion results seen in the Phase 2 study and results are expected in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top